Akebia announces late filing of its second quarter earnings and Form 10-Q
Akebia reaffirms 2023 net product revenue guidance of $175 - $180 million
Akebia believes its cash resources as of June 30, 2023 will be sufficient to fund its current operating plan through at least the next twelve months
Akebia expects to resubmit NDA for vadadustat as a treatment for anemia due to CKD in adult patients on dialysis in Q3 2023
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.